Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

<< Previous

Bullboard Posts

Next >>

Post by MetzGERon Jan 12, 2021 12:15pm

150 Views

Post# 32276422

Jerry Shapiro has his BIGGEST HOPE IN RCH-01

Watch at Minute 41:40:

https://www.instagram.com/tv/B_22YWXHE0R/

jerry Shapiro is a well known hair loss specialist. After the Phase II results of Shiseido He gave his Big enthusiasm about hair loss Therapy with dermal sheath Cup cells. He is very excited After the clinical results and thinks that a lower Dose of cells (200.000 cells or 150.000 cells or Even lower) will give much better results.

Very proud of RCH-01

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals